Effect of Polyethylene Glycol Loxenatide Treatment on Body Weight in Patients With Type 2 Diabetes With Different Body Mass Index: A Retrospective Real-World Study.
Real-world data on the effect of polyethylene glycol loxenatide (PEG-Loxe) in patients with Type 2 diabetes mellitus (T2DM) with normal body mass index (BMI) are lacking. Therefore, this study aims to observe the effect of PEG-Loxe on the weight of patients with T2DM with different BMIs.
This single-center, retrospective real-world study included patients with T2DM, aged ≥ 18 years, and receiving PEG-Loxe/sodium-glucose cotransporter 2 inhibitor (SGLT2i). The primary endpoint was change in body weight after 24 weeks of treatment. Secondary endpoints included proportion of patients with body weight reduction < 5.0% and < 10%, changes in BMI, and glycosylated hemoglobin (HbA1c).
Overall, 487 patients treated with SGLT2i or PEG-Loxe were identified; after propensity score matching, 68 patients were included in each group. After 24 weeks, the mean change in body weight and BMI was -1.2 (-2.3, -0.1) and -0.4 (-0.8, -0.1) in the PEG-Loxe group and -2.4 (-3.5, -1.3) and -0.7 (-1.1, -0.4) in the SGLT2i group. A ≥ 5% and ≥ 10% weight loss was noted by 32.4% and 8.8% of patients in the PEG-Loxe group, with a mean change in HbA1c (%) of -1.48 (-1.98, -0.99). Weight loss (≥ 5%) in obese patients (BMI > 28 kg/m2) was greater (PEG-Loxe: 53.3%, SGLT2i: 57.1%) compared to patients with 24 ≤ BMI < 28 kg/m2 (PEG-Loxe: 25.7%, SGLT2i: 41.4%) and BMI < 24 kg/m2 (PEG-Loxe: 27.8%, SGLT2i: 28%).
PEG-Loxe resulted in weight loss and glycemic control in patients with T2DM. The weight loss was negatively correlated with baseline BMI without excessive weight loss in normal BMI, supporting PEG-Loxe's use in this group. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2400087532.
This single-center, retrospective real-world study included patients with T2DM, aged ≥ 18 years, and receiving PEG-Loxe/sodium-glucose cotransporter 2 inhibitor (SGLT2i). The primary endpoint was change in body weight after 24 weeks of treatment. Secondary endpoints included proportion of patients with body weight reduction < 5.0% and < 10%, changes in BMI, and glycosylated hemoglobin (HbA1c).
Overall, 487 patients treated with SGLT2i or PEG-Loxe were identified; after propensity score matching, 68 patients were included in each group. After 24 weeks, the mean change in body weight and BMI was -1.2 (-2.3, -0.1) and -0.4 (-0.8, -0.1) in the PEG-Loxe group and -2.4 (-3.5, -1.3) and -0.7 (-1.1, -0.4) in the SGLT2i group. A ≥ 5% and ≥ 10% weight loss was noted by 32.4% and 8.8% of patients in the PEG-Loxe group, with a mean change in HbA1c (%) of -1.48 (-1.98, -0.99). Weight loss (≥ 5%) in obese patients (BMI > 28 kg/m2) was greater (PEG-Loxe: 53.3%, SGLT2i: 57.1%) compared to patients with 24 ≤ BMI < 28 kg/m2 (PEG-Loxe: 25.7%, SGLT2i: 41.4%) and BMI < 24 kg/m2 (PEG-Loxe: 27.8%, SGLT2i: 28%).
PEG-Loxe resulted in weight loss and glycemic control in patients with T2DM. The weight loss was negatively correlated with baseline BMI without excessive weight loss in normal BMI, supporting PEG-Loxe's use in this group. Trial Registration: Chinese Registry of Clinical Trials: ChiCTR2400087532.
Authors
Xu Xu, Dong Dong, Xu Xu, Zheng Zheng, Liu Liu, Duan Duan, Hu Hu, Bao Bao, Zhang Zhang
View on Pubmed